Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia

Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (Cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Sander, Frida Ewald, Rydström, Anna, Bernson, Elin, Kiffin, Roberta, Riise, Rebecca, Aurelius, Johan, Anderson, Harald, Brune, Mats, Foà, Robin, Hellstrand, Kristoffer, Thorén, Fredrik B., Martner, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884940/
https://www.ncbi.nlm.nih.gov/pubmed/26863635
http://dx.doi.org/10.18632/oncotarget.7210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884940/
https://www.ncbi.nlm.nih.gov/pubmed/26863635
http://dx.doi.org/10.18632/oncotarget.7210

Ejemplares similares